Overview of a Reg A+: Invest $100 or more in this Mini-IPO. Alzamend Neuro™ is raising up to $50 million
In the past, only wealthy investors, venture capitalists, and private equity firms have had the opportunity to invest via special securities in private to public transactions. That has changed as of June 2015. In light of this change, we are now allowed to invite existing investors, friends, associates and the general public to participate in the growth of Alzamend Neuro™, Inc.
You can help support the Alzamend Neuro™ mission and participate in the Company as an equity shareholder, too. For as little as $100.00, you can participate as an owner. Alzamend Neuro™ currently has been qualified by the SEC to raise $50,000,000 dollars using the Reg A+ exemption. This allows the Company to accept investment from all types of investors including accredited, non-accredited and institutional.
By selecting the Invest Now button above, you can review the Offering Statement and Offering Circular and is where you can get more information on how to invest.
“I remember, like it was just yesterday, my grandmother no longer recognized me and worse yet, feared me as if I was a stranger. That was my first true experience of what Alzheimer’s is”. Later I would learn about and experience more than 6 direct family members systematically consumed by the disease, and watched helplessly.” – Chairman Milton “Todd” Ault III
Through his personal experience and diligent study of the status of treatments, and the landscape of medical technology, Mr. Ault, chose the USF Health/Byrd Alzheimer's Institute and their intellectual property portfolio and formed Alzamend Neuro™ as his starting point to make a difference. With twenty-five years of experience on Wall Street at buying and selling companies as an activist, his relentless passion for business and technology has culminated in a commitment to depart from the traditional while forging ahead with a disruptive path to financing the commercialization and the discovery of future solutions.
Mr. Ault was quick to recognize the opportunity to make a difference in routine medical procedures that at times resulted in fatal consequences. He founded and launched Patient Safety Technologies Inc., believing in the impact of bar-coded sponge technology, long before anyone else would support it. It has now become the standard of care in operating rooms around the world, saving countless lives and subsequent lawsuits annually.
Providing a team of Operational and Financial executives with proven track records, Mr. Ault has assembled an all-star cast to move this vision forward, without burdening the company with excessive overhead.